Antiplatelet Therapy in Patients Without a Coronary Stent and Mortality After Noncardiac Surgery

This study aimed to investigate the association between perioperative antiplatelet (anti-PLT) therapy and 90-d mortality after elective noncardiac surgery.

This retrospective cohort study analyzed the medical records of adult patients aged 18 y and older who were admitted to a single tertiary academic hospital between January 1, 2012 and December 31, 2018 for planned elective noncardiac surgery. All patients with a history of coronary artery stent insertion before the day of surgery were excluded from the analysis. Propensity score matching and conditional logistic regression analysis were used for statistical analysis.

After propensity score matching, a total of 24,710 patients (12,355 in each group) were included in the final analysis. Ninety-day mortalities in the anti-PLT and non-anti-PLT groups were 0.9% (107/12,355) and 1.2% (143/12,355), respectively. The anti-PLT group showed significantly lower odds for 90-d mortality (by 27%) than the non-anti-PLT group (odds ratio, 0.73; 95% confidence interval, 0.55-0.95; P = 0.017). In the sensitivity analysis of the anti-PLT group classified according to the drug type and combination, the aspirin and clopidogrel subgroups significantly showed 23% and 41% lower odds for 90-d mortality compared with the non-anti-PLT group, respectively. The dual anti-PLT groups showed no significant difference in 90-d mortality (P = 0.658).

Perioperative anti-PLT therapy (aspirin, clopidogrel, or dual anti-PLT therapy) was associated with lower 90-d mortality after elective noncardiac surgery in adult surgical patients without a coronary stent. This association was most evident in patients on a monotherapy of aspirin or clopidogrel.